Log In
BCIQ
Print this Print this
 

Idylla KRAS Mutation Test

Also known as: Idylla (formerly Apollo)

  Manage Alerts
Collapse Summary General Information
Company Biocartis Group N.V.
DescriptionAutomated in vitro diagnostic that detects 21 mutations in the K-Ras (KRAS) oncogene from tumor samples in about 2 hours
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetect BRAF mutations; Detect K-Ras (KRAS) mutations in colorectal cancer
Regulatory Designation
PartnerAmgen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/03/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today